להלן הודעת חברת אסטרהזניקה ישראל:
We are pleased to inform you that LYNPARZA has been approved and registered in Israel.
LYNPARZA is the first and the only PARPi that has been approved.
The PARPi harms DNA damage repair mechanisms and causes the death of cancer cells in ovarian cancer patients carrying the BRCA gene mutation.
LYNPARZA is indicated as maintenance treatment for platinum-sensitive relapsed, BRCA-mutated ovarian cancer patients, that respond to platinum-based chemotherapy.
In addition, LYNPARZA is the first precision medicine (directed therapy) for ovarian cancer.